UNSPSC 51312401: Chloropyramine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H20ClN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2K3L8O9SOV, chemically known as 1,2-ethanediamine, n-((4-chlorophenyl)methyl)-n,n-dimethyl-n-2-pyridinyl- (9ci) but generally known as chloropyramine, which bears US NIH Compound Identifier 25295. European Medicines Agency schedules Chloropyramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06194MIG.

UNSPSC 51312401 Chloropyramine is a Commodity code that in practice encompasses pharmaceutical procurement by state and local health agencies, though recent solicitations show broader demand for emergency medical supplies, generic pharmaceuticals, and over-the-counter products rather than chloropyramine specifically. State and local buying under this code spans county health departments, state HHS commissions, and multistate cooperative purchasing alliances procuring for participating municipalities and government facilities. The work being solicited includes naloxone and drug deactivation systems for community health initiatives, direct-to-manufacturer pharmaceutical distribution programs, and generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers—all tied to health and emergency-response operations rather than a single named active pharmaceutical ingredient.

Recent activity appears concentrated in Florida and the Upper Midwest with coordination through multistate vehicles. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission released RFI HHS0017013 (posted April 3, 2026, same-day response deadline) to gather vendor capabilities on direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon through three authorized wholesalers, with a two-year contract term effective July 1, 2026.